TRV-chair vs Manual Repositioning Maneuver in Treatment of Benign Paroxysmal Positional Vertigo

Can Benign Paroxysmal Positional Vertigo (BPPV) be Treated Faster and More Efficiently by Using a Mechanical Rotational Chair Compared to the Traditional Manual Repositioning Maneuvers?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03871413

Enrollment

170

Registered

2019-03-12

Start date

2019-04-01

Completion date

2019-12-01

Last updated

2020-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPPV

Keywords

Benign Paroxysmal Positional Vertigo, Vertigo, Dizziness, Vestibular Diseases, Epley Maneuver, TRV-chair, Repositioning chair

Brief summary

Comparison of treatment efficacy of a mechanical rotational chair (TRV-chair) vs. manual repositioning maneuvers in BPPV

Detailed description

Open-label, randomized controlled trial comparing manual repositioning maneuvers with a mechanical rotational chair (TRV-chair) in diagnosing and treating BPPV. Patients with suspected BPPV will be randomized to either manual repositioning maneuvers or the TRV-chair.

Interventions

DEVICETRV-chair

Repositioning maneuvers in TRV-chair

PROCEDUREManual repositioning maneuver

Treatment with manual repositioning maneuver

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Characteristic (for BPPV) positional nystagmus * Positive Dix-Hallpike * Positive supine roll test * Medical history compatible with BPPV

Exclusion criteria

* Treatment in TRV-chair within the last 6 months * Exclusion of BPPV diagnosis * Lack of treatment cooperation * Known cerebral aneurism or cerebral hemorrhage * Diagnosed and treated for BPPV within the past month * Treatment with sedating anti-histamines within the past 7 days

Design outcomes

Primary

Measure	Time frame	Description
Number of treatments	2 years	Number of treatment necessary to achieve resolution of vertigo and nystagmus
Treatment success after first treatment	2 years	Number of subjects achieving resolution of vertigo and nystagmus after one treatment

Secondary

Measure	Time frame	Description
Dizziness Handicap Inventory (DHI) questionnaire	2 years	Comparison of pre-treatment score and post-treatment score
Adverse events	2 years	Registration of adverse events

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026